ライフサイエンスコーパス: pancreas transplantation

1 bstruction is an uncommon complication after pancreas transplantation.

2 phan-ketoglutarate (HTK) compared with UW in pancreas transplantation.

3 isky and technically challenging whole-organ pancreas transplantation.

4 ainage should be the procedure of choice for pancreas transplantation.

5 safe and effective after simultaneous kidney-pancreas transplantation.

6 tely a 1:440 risk of spinal cord ischemia in pancreas transplantation.

7 l has historically exceeded that of solitary pancreas transplantation.

8 plied the two-layer method to clinical whole-pancreas transplantation.

9 3 beyond 3 months after simultaneous kidney-pancreas transplantation.

10 e of surgery may have a protective effect in pancreas transplantation.

11 iteria in order to expand the donor pool for pancreas transplantation.

12 obstacle when deciding whether to recommend pancreas transplantation.

13 ular complications after combined kidney and pancreas transplantation.

14 metabolism are of particular significance in pancreas transplantation.

15 D-BMI of 30 kg/m to decline donor offers for pancreas transplantation.

16 py for metabolic control) underwent solitary pancreas transplantation.

17 when compared with the consistent success of pancreas transplantation.

18 ost disease (GVHD) after simultaneous kidney-pancreas transplantation.

19 ients with significant CAD to safely undergo pancreas transplantation.

20 sulin-dependent diabetics were evaluated for pancreas transplantation.

21 n a cohort of diabetic patients referred for pancreas transplantation.

22 stula, and arterioenteric fistula related to pancreas transplantation.

23 lso be the case in a highly complex field as pancreas transplantation.

24 gnosing rejection or graft dysfunction after pancreas transplantation.

25 isone therapy are recognized consequences of pancreas transplantation.

26 long-term risk-benefit ratio of FK506 after pancreas transplantation.

27 ted a mean of 14.5 months (range 1-81) after pancreas transplantation.

28 d glucose metabolism remained abnormal after pancreas transplantation.

29 observed in glycemic levels after successful pancreas transplantation.

30 would have a similar or even worse impact on pancreas transplantation.

31 2 would be considered a contraindication for pancreas transplantation.

32 the T2D patients who would benefit most from pancreas transplantation.

33 ievable in type 1 diabetes (T1D) by islet or pancreas transplantation.

34 experts' recommendations for the practice of pancreas transplantation.

35 readmissions after kidney, liver, and kidney-pancreas transplantation.

36 ciency virus (HIV) (PLWH) who have undergone pancreas transplantation.

37 nodeficiency virus (PLWH) who have undergone pancreas transplantation.

38 ble periods of warm ischemic damage prior to pancreas transplantation.

39 act of recipient BMI on graft outcomes after pancreas transplantation.

40 patient mortality after simultaneous kidney-pancreas transplantation.

41 eat CMV disease approximately 6 months after pancreas transplantation.

42 iding the choice for prophylactic therapy in pancreas transplantation.

43 have a significant impact on the success of pancreas transplantation.

44 here is approximately a 1:440 risk of SCI in pancreas transplantation.

45 the role of SRL on native kidney function in pancreas transplantation.

46 ther laparoscopy can reduce the morbidity of pancreas transplantation.

47 most common cause of early graft loss after pancreas transplantation.

48 eexploration was defined as within 1 week of pancreas transplantation.

49 d to an increasing number of indications for pancreas transplantation.

50 d whether NG decompression is necessary post pancreas transplantation.

51 ased immunosuppression has been effective in pancreas transplantation.

52 little information concerning obesity after pancreas transplantation.

53 ophylaxis of CMV disease after kidney and/or pancreas transplantation.

54 We present two cases of acute GVHD following pancreas transplantation.

55 rmation, have been well documented following pancreas transplantation.

56 ype 1 diabetes mellitus underwent successful pancreas transplantation (108 kidney/pancreas transplant

57 in diabetic patients awaiting kidney and/or pancreas transplantation; (2) using the two radionuclide

58 nine models of the anatomical alterations of pancreas transplantation: 70% partial pancreatectomy (PP

59 s-kidney transplantation (SPK); 44 underwent pancreas transplantation after previous kidney transplan

60 Pancreas transplantation aims to restore physiologic nor

61 neous pancreas-kidney transplantation (SPK), pancreas transplantation alone (PTA), and pancreas after

62 dney transplantation (PAK); and 15 underwent pancreas transplantation alone (PTA).

63 us pancreas-kidney transplantation (SPK) and pancreas transplantation alone can improve long-term pat

64 Of the simultaneous pancreas and kidney, pancreas transplantation alone, and PAK transplant recip

65 RESULTS.: Simultaneous pancreas and kidney, pancreas transplantation alone, and pancreas after kidne

66 pancreas after kidney transplantation, and 8 pancreas transplantations alone.

67 Kidney-pancreas transplantation alters the diabetic milieu; yet

68 to examine de novo HLA antibodies following pancreas transplantation and clearly defines a high-risk

69 CEUS yields useful information after pancreas transplantation and has been proven a sensitive

70 he TLM of pancreas preservation before whole-pancreas transplantation and islet isolation show promis

71 afe and effective long-term primary agent in pancreas transplantation and provides excellent long-ter

72 I], 1.22-7.39; P = 0.02) along with solitary pancreas transplantation and Rej+/DSA+ were associated w

73 sustain the relevance of early referral for pancreas transplantation and the importance of pancreas

74 Pancreas transplantation and the infusion of cadaveric i

75 cessful pancreas transplantation (108 kidney/pancreas transplantation) and another 28 patients with t

76 ng 18 HNF1B patients receiving SKT or kidney-pancreas transplantation, and in vitro experiments inclu

77 GVHD is a rare, often fatal, complication of pancreas transplantation, and its presentation appears t

78 e first year after kidney, heart, liver, and pancreas transplantation, and they could be associated w

79 patients with type 1 diabetes mellitus after pancreas transplantation, and we did not find any studie

80 risk indices externally validated for solid pancreas transplantation, and when validated without rec

81 Therefore, the advantages of pancreas transplantation appear to clearly surpass poten

82 ical complications after combined kidney and pancreas transplantation are a major source of morbidity

83 Patient and graft survival after pancreas transplantation are superior in higher volume c

84 vidence-based guidelines for the practice of pancreas transplantation are yet to be established.

85 psies detect complications after whole-organ pancreas transplantation, are useful in guiding therapy,

86 first case report of simultaneous liver and pancreas transplantation as treatment of WRS in a small

87 An overview of 30 years of pancreas transplantation at a high volume center.

88 ods A cohort of adult patients who underwent pancreas transplantation at a tertiary institution over

89 leted of the results and complications after pancreas transplantation at one institution.

90 compared outcomes of 153 patients undergoing pancreas transplantation at our institution over a 3.5-y

91 donors and 431 recipients who had undergone pancreas transplantation at the Oxford Transplant Centre

92 ing specific hurdles for individuals seeking pancreas transplantation because they are frequently dis

93 enging in the setting of simultaneous kidney-pancreas transplantation, because a reduction in immunos

94 Clinical pancreas transplantation began at the University of Minn

95 apy provides effective immunosuppression for pancreas transplantation, but the optimal use of this dr

96 induction of immunsuppression for kidney and pancreas transplantation, but the two agents have not be

97 e of this study is to analyze the outcome of pancreas transplantation by using a single dose of 30 mg

98 ney transplantation (SKT) or combined kidney-pancreas transplantation can be considered.

99 Pancreas transplantation can be very challenging in the

100 Combined kidney-pancreas transplantation (CKPT) with its associated eugl

101 Successful pancreas transplantation corrects abnormal glucose metab

102 y larger series, laparoscopic robot-assisted pancreas transplantation could become a new option for d

103 ntial for survival of patients with WRS, and pancreas transplantation cures their type I diabetes mel

104 al complications are a major disincentive to pancreas transplantation, despite the undisputed benefit

105 long-term patient survival, and all types of pancreas transplantation dramatically improve the qualit

106 5-year pancreas graft survival rate, 29.7%), pancreas transplantation evolved during the second decad

107 o combat type 1 diabetes (T1D) include donor pancreas transplantation, exogenous insulin administrati

108 The patients underwent isolated pancreas transplantation, following which, we have been

109 te mofetil (MMF) has been used in kidney and pancreas transplantation for almost 10 years.

110 Patients should rarely be excluded from pancreas transplantation for cardiac causes.

111 However, solitary pancreas transplantation for nonuremic patients with IDD

112 externally validating risk indices in solid pancreas transplantation for the outcomes of pancreas an

113 All patients undergoing pancreas transplantation from 2003 to 2010 were enrolled

114 a nonacute, combined, simultaneous liver and pancreas transplantation from a pediatric donor without

115 eports the comparative short-term results of pancreas transplantation from donors after circulatory d

116 pective cohort study of adults who underwent pancreas transplantation from January 1, 2010, through D

117 All consecutive pancreas transplantations from January 2008 until Decemb

118 Pancreas transplantation has an identity crisis and is a

119 Solitary pancreas transplantation has become a viable alternative

120 Pancreas transplantation has become the therapy of choic

121 A new surgical technique of pancreas transplantation has been developed with portal

122 Pancreas transplantation has been shown to fully restore

123 along with tacrolimus for > or =1 year after pancreas transplantation has not been studied in a large

124 ilure on hypertension by combined kidney and pancreas transplantation has not been studied.

125 Sirolimus (SRL) rescue in kidney-pancreas transplantation has not been well described.

126 ng-term safety and efficacy of tacrolimus in pancreas transplantation has not yet been demonstrated.

127 During the last 32 years, many problems in pancreas transplantation have been overcome and it may c

128 In conclusion, patients after pancreas transplantation have normal basal FFA turnover

129 %), nine IDDM patients after combined kidney-pancreas transplantation (HbA1c 5.8%), seven patients wi

130 ability score (P-PASS) are utilised in solid pancreas transplantation however no review has compared

131 tients with nephropathy before kidney and/or pancreas transplantation; however, controversy exists re

132 Solitary pancreas transplantation (ie, pancreas alone or pancreas

133 studies uniquely demonstrate that successful pancreas transplantation improves epinephrine response a

134 Pancreas transplantation improves glycemic control and m

135 d pancreas graft survivals after 30 years of pancreas transplantation in a high volume center.

136 We report successful combined liver-pancreas transplantation in a patient with primary scler

137 designed to evaluate the results of solitary pancreas transplantation in a protocol that uses the new

138 o induce recurrent autoimmune diabetes after pancreas transplantation in mice.

139 These results question the safety of pancreas transplantation in obese patients and suggest t

140 We report herein the results of pancreas transplantation in patients receiving primary t

141 zumab and rATG induction in adult kidney and pancreas transplantation in patients treated with simila

142 rsy persists over the safety and efficacy of pancreas transplantation in patients with insulin-depend

143 D) remains relatively uncommon compared with pancreas transplantation in patients with type 1 diabete

144 Pancreas transplantation in patients with type 2 diabete

145 survival, and glycemic control outcomes for pancreas transplantation in T2D and expressed a need to

146 We systematically reviewed the literature on pancreas transplantation in T2D patients including patie

147 Despite this growing interest in pancreas transplantation in T2D, no study has systematic

148 To evaluate the risks of pregnancy after pancreas transplantation in the cyclosporine era, we sur

149 ere are limited data on how kidney or kidney-pancreas transplantation influence continuous autonomic

150 Pancreas transplantation involves anatomical changes tha

151 rocesses that support optimal outcomes after pancreas transplantation irrespective of center volume.

152 Pancreas transplantation is a controversial form of ther

153 Combined liver-pancreas transplantation is a relatively uncommon proced

154 Simultaneous kidney pancreas transplantation is a safe and effective method

155 Simultaneous en bloc kidney and pancreas transplantation is a safe technique providing e

156 Pancreas transplantation is a successful procedure with

157 Pancreas transplantation is a successful treatment for a

158 If pancreas transplantation is a validated alternative for

159 Using current DCD criteria, pancreas transplantation is a viable alternative to DBD

160 This multicenter survey shows that FK506 in pancreas transplantation is associated with (1) a low ra

161 Enteric drainage in pancreas transplantation is complicated by an enteric le

162 For most practitioners who manage diabetes, pancreas transplantation is considered an extreme measur

163 l modifications or bariatric surgery, before pancreas transplantation is considered.

164 beta cell replacement via islet or pancreas transplantation is currently the only approach

165 ies to assess the hypothesis that successful pancreas transplantation is efficacious in normalizing e

166 As pancreas transplantation is exclusively performed among

167 The combination of MMF and tacrolimus after pancreas transplantation is highly effective and safe.

168 The most common cause of morbidity after pancreas transplantation is infection, particularly recu

169 The clinical success of pancreas transplantation is limited by the difficulty in

170 ss index on graft and patient survival after pancreas transplantation is not well known.

171 Pancreas transplantation is one of the most effective tr

172 Pancreas transplantation is performed at relatively few

173 d the experience of alemtuzumab induction in pancreas transplantation is still limited.

174 Graft thrombosis following pancreas transplantation is the leading non-immunologic

175 suggest that more widespread application of pancreas transplantation is warranted.

176 m of this study was to assess whether kidney-pancreas transplantation (KPT) compromises the prognosis

177 Pancreas transplantation may also improve the course of

178 mia and apparent insulin insensitivity after pancreas transplantation may be due to increased less po

179 high risk and candidates for combined kidney-pancreas transplantation may be monitored more frequentl

180 hough uncommon, intestinal obstruction after pancreas transplantation may have atypical etiologies.

181 ion episode, and interval between kidney and pancreas transplantation more than 1 year.

182 Since the introduction of pancreas transplantation more than 40 years ago, efforts

183 om organ donors considered inappropriate for pancreas transplantations must be evaluated.

184 Therefore, in the context of islet or pancreas transplantation, newly transplanted beta-cells

185 Pancreas transplantation normalized only insulin-mediate

186 e retrospectively investigated the impact of pancreas transplantation on cardiovascular disease risk

187 To assess the effect of pancreas transplantation on free fatty acid (FFA) and gl

188 the impact of preemptive simultaneous kidney-pancreas transplantation on recipient and graft outcomes

189 iberations on issues regarding the impact of pancreas transplantation on the management of diabetes w

190 9 jury deliberations regarding the impact of pancreas transplantation on the treatment of diabetic pa

191 n patients with long-standing T1D via kidney-pancreas transplantation or in diabetic mice by treatmen

192 creased to 134/77 mm Hg 1 month after kidney/pancreas transplantation (P<0.001) and decreased further

193 he main factors limiting potential uptake of pancreas transplantation, particularly in the United Kin

194 , alternative method for obtaining tissue in pancreas transplantation patients with graft dysfunction

195 To assess the long-term outcome of kidney/pancreas transplantation, patients were identified who h

196 All pancreas transplantations performed in our center from J

197 received combined intraperitoneal kidney and pancreas transplantation presented at 16 and 11 months a

198 he results and complications of the first 59 pancreas transplantation procedures performed at one ins

199 The First World Consensus Conference on Pancreas Transplantation provided 49 jury deliberations

200 e first to evaluate the efficacy of IGL-1 in pancreas transplantation (PT) compared with the Universi

201 Pancreas transplantation (PT) is an effective treatment

202 f diabetic neuropathy (DN) on outcomes after pancreas transplantation (PT) is scarce.

203 BACKGROUND.: Pancreas transplantation (PT) provides the best glycemic

204 Pancreas transplantation (PTX) improves diabetic microva

205 Pancreas transplantation (PTX) improves lipids in patien

206 Reproductive hormone function after pancreas transplantation (PTX) is unknown as it has not

207 diabetes mellitus are inconsistently offered pancreas transplantation (PTx), contributing to a dramat

208 We analyzed 30 simultaneous kidney-pancreas transplantations receiving tacrolimus, mycophen

209 ped hypoglycemic clamp studies in successful pancreas transplantation recipients to assess epinephrin

210 Pancreas transplantation remains a major surgery with po

211 oration of hypoglycemic counterregulation by pancreas transplantation remains stable in successful pa

212 Pancreas transplantation remains the gold standard for t

213 egalovirus (CMV) disease after kidney and/or pancreas transplantation remains unclear.

214 Successful pancreas transplantation requires surgical expertise and

215 oration for suspected graft thrombosis after pancreas transplantation resulted in a negative laparoto

216 Successful kidney/pancreas transplantation results in a marked improvement

217 been 6 cases of spinal cord ischemia during pancreas transplantation since 2002.

218 There have been 6 cases of SCI during pancreas transplantation since 2002.

219 BKVAN) in the setting of simultaneous kidney-pancreas transplantation (SKPT) has been inadequately st

220 Simultaneous cadaver kidney and pancreas transplantation (SPK) and living-donor kidney t

221 2 patients who underwent simultaneous kidney-pancreas transplantation (SPK) between 1993 and 1997 to

222 pancreas transplants (17 simultaneous kidney-pancreas transplantation [SPK], 5 pancreas after kidney

223 ransplantation (KTx) and simultaneous kidney-pancreas transplantation (SPKTx).

224 idney transplantations (SPK) and 56 solitary pancreas transplantations (SPT) performed at the Univers

225 Pancreas transplantation survival (complete insulin inde

226 may be a metabolic consequence of successful pancreas transplantation that results in EW gain in a pr

227 To improve the physiology of pancreas transplantation, the authors developed a new te

228 At 1 month after kidney/pancreas transplantation, the average number of antihype

229 , in patients undergoing simultaneous kidney/pancreas transplantation, the entity of dissynchronous p

230 ss formation have been well documented after pancreas transplantation, the occurrence of small bowel

231 e insulin independence following solid-organ pancreas transplantation, the secondary complications of

232 ressive agents may allow simultaneous kidney-pancreas transplantation to be performed without antilym

233 matically reviewed all risk indices in solid pancreas transplantation to compare their predictive abi

234 Islet transplantation is an alternative to pancreas transplantation to cure type 1 diabetes, but bo

235 niques have improved the success of solitary pancreas transplantations to the point where outcome is

236 erience with simultaneous en bloc kidney and pancreas transplantation using pediatric donors on 8 con

237 t standard technique for simultaneous kidney pancreas transplantation usually involves transplanting

238 The rate of first fracture after kidney-pancreas transplantation was 12.1% per patient year, res

239 Time interval between kidney and pancreas transplantation was 5.9 +/- 3.8 (4.8 [1.6-12.2]

240 Dialysis at simultaneous kidney-pancreas transplantation was an independent significant

241 The First World Consensus Conference on Pancreas Transplantation was convened for this purpose.

242 The risk of SCI in pancreas transplantation was estimated using the number

243 The risk of SCI in pancreas transplantation was estimated using the number

244 al failure who underwent simultaneous kidney-pancreas transplantation was found to have stage IV smal

245 Pancreas transplantation was indicated for patients with

246 Pancreas transplantation was performed by robot-assisted

247 Pancreas transplantation was performed using systemic ve

248 Pancreas transplantation was the most affected, followed

249 Using a porcine model of pancreas transplantation, we compared 5 h of static cold

250 ologic imaging, and greater understanding of pancreas transplantation, we hypothesized that ED could

251 the first 3 months after simultaneous kidney-pancreas transplantation were 15-20 ng/ml.

252 Changes in RIs after pancreas transplantation were a poor indicator of acute

253 of the risk indices derived for use in solid pancreas transplantation were not externally validated (

254 ive cell transfer and vascularized segmental pancreas transplantation were performed in mice.

255 In the study period, 1276 pancreas transplantations were included.

256 nd December 1, 1998, 147 simultaneous kidney/pancreas transplantations were performed at our center.

257 From July 4, 1994 until April 30, 1998, 147 pancreas transplantations were performed in 141 patients

258 Between 1976 and 2008, 569 pancreas transplantations were performed in Lyon and Gen

259 In the study period, 349 pancreas transplantations were performed.

260 As) are an invaluable resource in kidney and pancreas transplantation when vascular reconstruction is

261 ted hypotension is particularly important in pancreas transplantation where venous thrombosis is a ma

262 assessed, nor has it been determined whether pancreas transplantation, which not only obviates hypogl

263 n norepinephrine response was observed after pancreas transplantation, while glucagon responses to hy

264 excluded, as were those listed for solitary pancreas transplantation who had a serum creatinine leve

265 lent mid-term patient and graft survival for pancreas transplantation with acceptable complication ra

266 All patients underwent whole organ pancreas transplantation with bladder drainage and recei

267 l patients who underwent simultaneous kidney-pancreas transplantation with bladder drainage at our ce

268 Combining cadaver pancreas transplantation with living-donor kidney transp

269 omic function follows both kidney and kidney-pancreas transplantation with more pronounced improvemen

270 eir pancreas graft after simultaneous kidney-pancreas transplantation with P-E drainage underwent pan

271 Eighteen patients underwent pancreas transplantation with portal-enteric (P-E) drain

272 cemic control, inhibits wider application of pancreas transplantation with respect to reporting long-

273 results suggest that simultaneous kidney and pancreas transplantation with SE or PE drainage can be p

274 University of Wisconsin performs all pancreas transplantations with enteric drainage of exocr

275 CaDBD donors are suitable for routine pancreas transplantation without increasing EGF risk, an

276 he efficacy, risks, and costs of whole-organ pancreas transplantation (WOP) with the costs of isolate

277 entation of immunosuppression at the time of pancreas transplantation would protect the recipient fro